youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
INCY:NASDAQ
Incyte Corp
$115.71
arrow_downward
-1.04%(-1.22) 1D
$115.00
arrow_downward
-0.61% (-0.71)bedtimeAfter hours
Closed: Oct 23, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INCY...
Open
$116.75
High
$116.86
Low
$115.12
Mkt. cap
23.45B
Avg. vol.
1.72M
Volume
1.48M
P/E ratio
14.74
52-wk high
$132.58
52-wk low
$84.02
EPS
$7.85
Beta
0.74
Shares outstanding
202.70M
No. of employees
3K
Open
$116.75
High
$116.86
Low
$115.12
Mkt. cap
23.45B
Avg. vol.
1.72M
Volume
1.48M
P/E ratio
14.74
52-wk high
$132.58
52-wk low
$84.02
EPS
$7.85
Beta
0.74
Shares outstanding
202.70M
No. of employees
3K
News stories
From web sources and news partners
Seeking Alpha
·
2 hours ago
Genmab, Incyte team up to develop experimental colorectal cancer treatment (INCY:NASDAQ)
News Corp
·
2 days ago
Incyte Corp. stock outperforms competitors despite losses on the day
Zacks
·
2 days ago
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
Yahoo Finance
·
2 days ago
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
Profile
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
About Incyte Corp
CEO-
Employees2.84K
Founded2002
HeadquartersWilmington, Delaware, United States
SectorBiotechnology
Websiteincyte.com
Analyst ratings
Based on 21 analysts giving stock ratings to INCY in the past 3 months
Buy
Buy
11
Hold
10
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for INCY in the last 3 months.
Highest
Current $115.71
$157.00 (+35.68%)
Average
$131.80 (+13.91%)
Lowest
$104.00 (-10.12%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Mitchell Kapoor H.C. Wainwright | Buy | Reiterated | $152.00 | +31.4% | 10/23/2026 |
Tara Bancroft TD Cowen | Buy | Maintained | $140.00 | +21% | 10/21/2026 |
Allison Bratzel Piper Sandler | Buy | Maintained | $130.00 | +12.3% | 10/21/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Maintained | $140.00 | +21% | 10/19/2026 |
John Newman Canaccord Genuity | Buy | Maintained | $152.00 | +31.4% | 10/19/2026 |
Brian Abrahams RBC Capital | Hold | Maintained | $114.00 | -1.5% | 10/16/2026 |
Derek Archila Wells Fargo | Hold | Maintained | $128.00 | +10.6% | 10/15/2026 |
Srikripa Devarakonda Truist Financial | Hold | Maintained | $115.00 | -0.6% | 10/14/2026 |
Etzer Darout Barclays | Buy | Maintained | $139.00 | +20.1% | 10/13/2026 |
Evan Seigerman BMO Capital | Hold | Maintained | $130.00 | +12.3% | 10/12/2026 |
Stephen Willey Stifel Nicolaus | Buy | Maintained | $157.00 | +35.7% | 10/05/2026 |
Jessica Fye J.P. Morgan | Hold | Maintained | $123.00 | +6.3% | 09/28/2026 |
Jeffrey Walch Bernstein | Hold | Maintained | $104.00 | -10.1% | 09/25/2026 |
Matt Phipps William Blair | Hold | Maintained | - | - | 08/19/2026 |
Salim Syed Mizuho Securities | Buy | Maintained | $137.00 | +18.4% | 08/03/2026 |
Andrew Berens Leerink Partners | Buy | Maintained | $155.00 | +34% | 08/03/2026 |
Salveen Richter Goldman Sachs | Hold | Maintained | $118.00 | +2% | 07/29/2026 |
Ashwani Verma UBS | Hold | Maintained | $113.00 | -2.3% | 07/28/2026 |
Michael Schmidt Guggenheim | Buy | Maintained | $150.00 | +29.6% | 07/28/2026 |
Judah Frommer Morgan Stanley | Hold | Maintained | $119.00 | +2.8% | 07/29/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $120.00 | +3.7% | 07/28/2026 |
Marc Frahm TD Cowen | Buy | Maintained | $138.00 | +19.3% | 07/28/2026 |
Unknown Analyst Bernstein | Hold | Maintained | - | - | 06/01/2026 |
Unknown Analyst J.P. Morgan | Hold | Maintained | $105.00 | -9.3% | 05/20/2026 |
Unknown Analyst Guggenheim | Buy | Maintained | $130.00 | +12.3% | 05/04/2026 |
Unknown Analyst Argus Research | Buy | Maintained | $115.00 | -0.6% | 04/30/2026 |
Faisal Khurshid Jefferies | Hold | Downgraded | $94.00 | -18.8% | 03/15/2026 |
Unknown Analyst Evercore ISI | Hold | Maintained | $110.00 | -4.9% | 03/05/2026 |
Next call in 4 days
Thu, Oct 29, 8:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$3.85
Revenue / Est. (USD)
- / 1.47B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.37B | 1.51B | 1.27B | 1.67B |
Cost of goods sold | 605.58M | 732.55M | 620.43M | 621.91M |
Cost of revenue | 605.58M | 732.55M | 620.43M | 621.91M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 328.29M | 388.96M | 327.06M | 350.72M |
Operating expense | 328.29M | 388.96M | 327.06M | 350.72M |
Total operating expenses | 933.87M | 1.12B | 947.49M | 972.63M |
Operating income | 432.11M | 385.32M | 325.19M | 701.41M |
Other non operating income | 3.25M | 4.22M | 1.75M | 5.26M |
EBT including unusual items | 482.31M | 389.94M | 343.60M | 751.51M |
EBT excluding unusual items | 461.55M | 419.71M | 360.06M | 744.21M |
Income tax expense | 58.14M | 90.66M | 40.27M | 165.91M |
Effective tax rate | 12.05% | 23.25% | 11.72% | 22.08% |
Other operating expenses | - | - | - | - |
Net income | 424.17M | 299.28M | 303.33M | 585.60M |
Net profit margin | 31.05% | 19.86% | 23.83% | 34.98% |
Earnings per share | 2.26 | 1.80 | 1.81 | 3.09 |
Interest and investment income | 26.78M | 30.75M | 33.69M | 38.12M |
Interest expense | -592.00K | -582.00K | -569.00K | -582.00K |
Net interest expenses | 26.19M | 30.17M | 33.12M | 37.54M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 456.13M | 409.30M | 348.99M | 727.89M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1